Serum levels of arginase I are associated with left ventricular function after myocardial infarction

Bekpınar, Seldağ; Gürdöl, Figen; Ünlüçerçi, Yeşim; Develi, Seval; Yılmaz, Akar

doi:10.1016/j.clinbiochem.2011.06.003

Cited by 20 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several studies regarding increased arginase activity in humans (19) and in experimental animal models (20,21). Jung et al reported that arginase activity was upregulated during ischemia-reperfusion in mouse myocardial tissue.…”

Section: Discussionmentioning

confidence: 99%

“…In parallel with these findings, increased arginase activity was also shown to contribute to vascular endothelial dysfunction in diabetes (22). Moreover, it was demonstrated that serum arginase I activity was significantly increased and that serum arginine levels were depleted in humans after myocardial infarction (19). These authors demonstrated that arginase expression and activity were upregulated in ischemic myocardium and coronary arterioles following ischemia-reperfusion (19).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Arginase activity and nitric oxide levels in patients with obstructive sleep apnea syndrome

Yüksel¹,

Okur²,

Pelin³

et al. 2014

Clinics

View full text Add to dashboard Cite

OBJECTIVE:Obstructive sleep apnea syndrome is characterized by repetitive obstruction of the upper airways, and it is a risk factor for cardiovascular diseases. There have been several studies demonstrating low levels of nitric oxide in patients with obstructive sleep apnea syndrome compared with healthy controls. In this study, we hypothesized that reduced nitric oxide levels would result in high arginase activity. Arginase reacts with L-arginine and produces urea and L-ornithine, whereas L-arginine is a substrate for nitric oxide synthase, which produces nitric oxide.METHODS:The study group consisted of 51 obstructive sleep apnea syndrome patients (M/F: 43/8; mean age 49±10 years of age) and 15 healthy control subjects (M/F: 13/3; mean age 46±14 years of age). Obstructive sleep apnea syndrome patients were divided into two subgroups based on the presence or absence of cardiovascular disease. Nitric oxide levels and arginase activity were measured via an enzyme-linked immunosorbent assay of serum samples.RESULTS:Serum nitric oxide levels in the control subjects were higher than in the obstructive sleep apnea patients with and without cardiovascular diseases (p<0.05). Arginase activity was significantly higher (p<0.01) in obstructive sleep apnea syndrome patients without cardiovascular diseases compared with the control group. Obstructive sleep apnea syndrome patients with cardiovascular diseases had higher arginase activity than the controls (p<0.001) and the obstructive sleep apnea syndrome patients without cardiovascular diseases (p<0.05).CONCLUSION:Low nitric oxide levels are associated with high arginase activity. The mechanism of nitric oxide depletion in sleep apnea patients suggests that increased arginase activity might reduce the substrate availability of nitric oxide synthase and thus could reduce nitric oxide levels.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Arginase activity and nitric oxide levels in patients with obstructive sleep apnea syndrome

Yüksel¹,

Okur²,

Pelin³

et al. 2014

Clinics

View full text Add to dashboard Cite

show abstract

“…Therefore, the induction of NOS arginase has been investigated in the inflammatory cells of asthmatic lungs as pathophysiological evidence that the consumption of L-arginine by arginase may lead to the depletion of NO production and endothelial dysfunction; thus, the enlargement of bronchial smooth muscle associated with airway hyperresponsiveness (6–8). Furthermore, following catabolism by arginase, arginine is no longer available to NOS; thus, subsequent NO synthesis is diminished (9). …”

Section: Introductionmentioning

confidence: 99%

Assessment of serum arginase I as a type 2 diabetes mellitus diagnosis biomarker in patients

Wang

Fang

Jin

et al. 2014

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Previous studies have reported that levels of serum arginase I are increased in certain diseases. However, the exact association between arginase I and diabetes mellitus (DM) has yet to be determined. The aim of the present study was to investigate the correlation between arginase I activity and DM to determine whether arginase I activity may be used as a diagnostic biomarker for DM. DM was induced by a streptozotocin injection, while the arginase inhibitor, citrulline, was administered daily. Serum levels of glucose, reactive oxygen species (ROS) and arginase I activity were analyzed, and quantitative polymerase chain reaction and western blot analysis were performed to detect the mRNA and protein expression levels of arginase I, respectively. In addition, western blot analysis was used to determine the protein expression of the Tie 2 receptor. Pearson’s analysis was used to determine the correlation between arginase I activity and Tie 2 expression, while concordance analysis was performed using the Cohen’s test to obtain the Kappa statistic. The results demonstrated that serum arginase I activity levels in the rats with DM were significantly elevated compared with the control group, and positively correlated with the blood glucose levels. In addition, the blood glucose and ROS levels were increased significantly in the rats with DM. Arginase I mRNA and protein expression levels were significantly elevated in the diabetic rats when compared with the control group, and Tie 2 expression levels increased and were shown to correlate with arginase I activity in the diabetic rats. In addition, arginase I activity was shown to correlate with glucose intolerance and post-load glucose values. Good concordance was observed between arginase I activity and the clinical diagnosis for DM (κ=0.876; P<0.001). Therefore, the results indicated that arginase I may function as a diagnostic biomarker for DM rats model.

show abstract

“…Endothelial nitric oxide synthase (eNOS) enzyme activity and nitric oxide level levels were significantly lower in acute myocardial infarction in presence or absence of macrovascular disease (21). The significant low serum nitric oxide level in patients with acute myocardial infarction could be attributed to increased activity of asymmetric dimethylarginine; an endogenous nitric oxide synthase inhibitor (22). Recently, Cavalca et al (2012) reported non significant changes in asymmetric dimethylarginine but significant increase in symmetric dimethylarginine in NSTEMI (23).…”

Section: Discussionmentioning

confidence: 97%

Significant Alteration of Nitrogen Species in Acute Myocardial Infarction Does Not Relate to The Site of Infarction

Al-Nimer

Alhusseiny

2014

Electron J Gen Med

View full text Add to dashboard Cite

show abstract

Serum levels of arginase I are associated with left ventricular function after myocardial infarction

Cited by 20 publications

References 28 publications

Arginase activity and nitric oxide levels in patients with obstructive sleep apnea syndrome

Arginase activity and nitric oxide levels in patients with obstructive sleep apnea syndrome

Assessment of serum arginase I as a type 2 diabetes mellitus diagnosis biomarker in patients

Significant Alteration of Nitrogen Species in Acute Myocardial Infarction Does Not Relate to The Site of Infarction

Contact Info

Product

Resources

About